Furthermore, combining tumor mRNA vaccines with immune checkpoint inhibitors (such as anti-PD-L1 antibodies) or other immunostimulants represents a combinatorial strategy that helps overcome immunosuppression in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.